MipSalus

MipSalus is a private, preclinical-stage biotech company pioneering the therapeutic application of Molecular Imprinted Polymers (MIPs). Its core technology platform creates synthetic, antibody-like binding sites within polymers to selectively capture and remove target molecules, such as amino acids, from the gut in a non-systemic manner. The company's initial focus is on developing a first-in-class oral treatment for all variants of Hyperphenylalaninemia (HPA), including Phenylketonuria (PKU). MipSalus operates with a lean team, is funded by founders, private investors, and public grants, and follows a strategy of achieving proof-of-concept before seeking partnerships for clinical development and commercialization.

Proprietary platform based on Molecular Imprinted Polymers (MIPs). Creates synthetic polymers with antibody-like binding sites for specific target molecules (e.g., amino acids). Designed for oral, non-systemic administration to bind and sequester targets in the GI tract for excretion, preventing their absorption into the bloodstream.

In PKU, MipSalus would compete against existing therapies like enzyme replacement (Palynziq) and chaperone (Kuvan) treatments, as well as strict dietary management. Its novel, non-systemic mechanism is its key differentiator. More broadly, the platform faces potential future competition from other emerging technologies targeting metabolite removal or gene therapies for metabolic diseases.